Kardigan, Inc.
Kardigan, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension on December 15, 2026. There are 4 upcoming events on record.
Cash runway is approximately 33.4 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| December 15, 2026 | Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension | Trial Milestone | Phase 2 |
| September 15, 2027 | A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy | Trial Milestone | Phase 2/Phase 3 |
| August 31, 2028 | Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study | Trial Milestone | Phase 2/Phase 3 |
| November 15, 2032 | A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy | Trial Milestone | Phase 3 |
Track KARD alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open KARD in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| September 30, 2026 | 8-K filed: Leadership change, Reg FD disclosure | Corporate | — |
| August 11, 2026 | Quarterly results filed (8-K) | Earnings | — |
| January 12, 2026 | A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL) | Trial Milestone | Phase 2 |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.